GlassScriptPhysician profile
William C Linville
NPI 1740711738
$7,654.62
in general payments reported to CMS, 2019-2025
34 companies · $2,635 in 2025
The $2,635 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.78 · 2021: $137 · 2022: $339 · 2023: $1,188 · 2024: $3,341 · 2025: $2,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,164.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,844.94 | 2023-2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $937.84 | 2021-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $878.46 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $368.83 | 2023-2025 | Glassia |
| Genzyme Corporation | $300.78 | 2024-2025 | |
| Inogen, INC. | $292.30 | 2023-2025 | Inogen |
| Pulmonx Corporation | $265.50 | 2023-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Insmed, INC. | $228.21 | 2023-2025 | Arikayce |
| Amgen INC. | $227.18 | 2023-2025 | Tezspire |
| Axsome Therapeutics, INC. | $216.01 | 2024-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $204.60 | 2023-2025 | Dupixent |
| United Therapeutics Corporation | $194.35 | 2023-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $174.56 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $156.38 | 2023-2025 | Zerbaxa, Winrevair, Recarbrio |
| Jazz Pharmaceuticals INC. | $146.23 | 2023-2025 | Xywav |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $137.69 | 2024-2025 | Acthar |
| Shionogi INC | $136.63 | 2023-2025 | Fetroja |
| Ethicon INC. | $136.42 | 2024 | Monarch Platform |
| Inspire Medical Systems, INC. | $126.16 | 2023-2025 | Inspire |
| Viatris Specialty LLC | $124.98 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $103.22 | 2024-2025 | Uptravi, Opsumit |
| Electromed, INC. | $82.03 | 2024-2025 | Smartvest |
| Grifols USA, LLC | $81.67 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Philips North America LLC | $53.10 | 2023-2024 | (Ak6) Vest Therapy |
| Genentech USA, INC. | $43.59 | 2024-2025 | Xolair |
| Fisher & Paykel Healthcare INC | $33.22 | 2023 | Fisher & Paykel Healthcare |
| Novartis Pharmaceuticals Corporation | $30.84 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $27.66 | 2025 | Lumryz |
| Baxter Healthcare | $19.66 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Ucb, INC. | $18.06 | 2024 | Briviact |
| Lilly USA, LLC | $17.00 | 2025 | Zepbound |
| Csl Behring | $16.51 | 2025 | Kcentra |
| Verona Pharma, INC. | $15.54 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $14.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Linville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.